Maiques-Diaz Alba, Somervaille Tim Cp
Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Epigenomics. 2016 Aug;8(8):1103-16. doi: 10.2217/epi-2016-0009. Epub 2016 Aug 1.
LSD1 (KDM1A; BHC110; AOF2) was the first protein reported to exhibit histone demethylase activity and has since been shown to have multiple essential roles in mammalian biology. Given its enzymatic activity and its high-level expression in many human malignancies, a significant recent focus has been the development of pharmacologic inhibitors. Here we summarize structural and biochemical knowledge of this important epigenetic regulator, with a particular emphasis on the functional and preclinical studies in oncology that have provided justification for the evaluation of tranylcypromine derivative LSD1 inhibitors in early phase clinical trials.
赖氨酸特异性去甲基化酶1(LSD1,又称KDM1A、BHC110、AOF2)是首个被报道具有组蛋白去甲基化酶活性的蛋白质,此后被证明在哺乳动物生物学中发挥多种重要作用。鉴于其酶活性以及在许多人类恶性肿瘤中的高表达,近期一个重要的研究重点是开发其药理学抑制剂。在此,我们总结了关于这种重要表观遗传调节因子的结构和生化知识,特别强调了肿瘤学方面的功能和临床前研究,这些研究为在早期临床试验中评估反苯环丙胺衍生物LSD1抑制剂提供了依据。